Recent Advances in Retinal Stem Cell Therapy.

Current molecular biology reports Pub Date : 2017-09-01 Epub Date: 2017-07-10 DOI:10.1007/s40610-017-0069-3
Sujoy Bhattacharya, Rajashekhar Gangaraju, Edward Chaum
{"title":"Recent Advances in Retinal Stem Cell Therapy.","authors":"Sujoy Bhattacharya,&nbsp;Rajashekhar Gangaraju,&nbsp;Edward Chaum","doi":"10.1007/s40610-017-0069-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Progress in stem cell research for blinding diseases over the past decade is now being applied to patients with retinal degenerative diseases and soon perhaps, glaucoma. However, the field still has much to learn about the conversion of stem cells into various retinal cell types, and the potential delivery methods that will be required to optimize the clinical efficacy of stem cells delivered into the eye.</p><p><strong>Recent findings: </strong>Recent groundbreaking human clinical trials have demonstrated both the opportunities and current limitations of stem cell transplantation for retinal diseases. New progress in developing <i>in vitro</i> retinal organoids, coupled with the maturation of bio-printing technology, and non-invasive high-resolution imaging have created new possibilities for repairing and regenerating the diseased retina and rigorously validating its clinical impact <i>in vivo</i>.</p><p><strong>Summary: </strong>While promising progress is being made, meticulous clinical trials with cells derived using good manufacturing practice, novel surgical methods, and improved methods to derive all of the neuronal cell types present in the retina will be indispensable for developing stem cell transplantation as a paradigm shift for the treatment of blinding diseases.</p>","PeriodicalId":72737,"journal":{"name":"Current molecular biology reports","volume":"3 3","pages":"172-182"},"PeriodicalIF":0.0000,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40610-017-0069-3","citationCount":"24","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current molecular biology reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40610-017-0069-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/7/10 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 24

Abstract

Purpose of review: Progress in stem cell research for blinding diseases over the past decade is now being applied to patients with retinal degenerative diseases and soon perhaps, glaucoma. However, the field still has much to learn about the conversion of stem cells into various retinal cell types, and the potential delivery methods that will be required to optimize the clinical efficacy of stem cells delivered into the eye.

Recent findings: Recent groundbreaking human clinical trials have demonstrated both the opportunities and current limitations of stem cell transplantation for retinal diseases. New progress in developing in vitro retinal organoids, coupled with the maturation of bio-printing technology, and non-invasive high-resolution imaging have created new possibilities for repairing and regenerating the diseased retina and rigorously validating its clinical impact in vivo.

Summary: While promising progress is being made, meticulous clinical trials with cells derived using good manufacturing practice, novel surgical methods, and improved methods to derive all of the neuronal cell types present in the retina will be indispensable for developing stem cell transplantation as a paradigm shift for the treatment of blinding diseases.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
视网膜干细胞治疗新进展。
综述的目的:在过去的十年中,干细胞研究在致盲疾病方面的进展现在正在应用于视网膜退行性疾病的患者,不久可能会应用于青光眼。然而,关于干细胞转化为各种视网膜细胞类型,以及优化干细胞进入眼睛的临床疗效所需的潜在递送方法,该领域仍有很多需要学习的地方。最近的发现:最近突破性的人体临床试验已经证明了干细胞移植治疗视网膜疾病的机会和目前的局限性。体外视网膜类器官的新进展,加上生物打印技术的成熟,以及非侵入性高分辨率成像,为病变视网膜的修复和再生创造了新的可能性,并严格验证了其在体内的临床效果。总结:虽然取得了令人鼓舞的进展,但使用良好的生产规范、新颖的手术方法和改进的方法获得视网膜中存在的所有神经细胞类型的细胞进行细致的临床试验,对于发展干细胞移植作为治疗致盲疾病的范式转变是必不可少的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Ion Channels and Regulation of Insulin Secretion in Beta-Cells Immunotherapy in the Treatment of Cancer: Today and Tomorrow Immunotherapy Options for Neuroblastoma: What is on the Horizon? NADPH Oxidase in Pancreatic β-Cell Function Insulin Secretion and the β-Cell 102 Years After the Discovery of the Hormone
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1